Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find
Portfolio Pulse from Lara Goldstein
Cybin Inc. (NYSE:CYBN) has shared interim results from its Phase 2 study of psilocybin analog CYB003 on Major Depressive Disorder (MDD). The results showed a significant reduction in depression symptoms three weeks after a single 12mg dose. The company also plans to share topline Phase 1 data for its proprietary deuterated DMT compounds, CYB004 and SPL028, before the end of the year. The stock price rose following the announcement of the interim results.
November 01, 2023 | 8:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cybin's Phase 2 results for CYB003 show significant potential in treating MDD. This positive news has already impacted the company's stock price.
The positive interim results from Cybin's Phase 2 study of CYB003 show significant potential in treating MDD. This news is highly relevant to the company and has already had a positive impact on the stock price, indicating investor confidence in the company's ongoing research and development efforts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100